Abstract 808P
Background
Human papillomavirus (HPV) is the cause of the majority of cervical cancer cases and has been suggested to be released as cell-free DNA (ctHPV DNA) into the circulation. We here analyse if ctHPV DNA could be detected in plasma from patients with locally advanced cervical cancer (LACC) and if ctHPV DNA could be used as a prognostic biomarker and/or to detect relapses earlier than by traditional methods.
Methods
74 patients with LACC were included, 66/74 had biopsies positive for one of 13 high-risk HPV-types using a bead-based assay. Droplet digital PCR (ddPCR) assays were developed for the HPV-types found. 418 longitudinal plasma samples from these 66 patients were then analysed using ddPCR assays for the corresponding HPV-type found in the biopsies. Results were correlated to tumor- and clinical characteristics.
Results
92.4% of pre-treatment plasmas were positive for ctHPV DNA. ctHPV DNA levels were correlated to tumor stage. Persistent ctHPV DNA in end-of-treatment or early follow-up (1-4 months after finished treatment) plasma were correlated with worse progression-free survival (log rank test, p < 0.001) compared to if ctHPV DNA was not found. The positive predictive value (PPV) of ctHPV-status at early follow-up for predicting disease progression was 87.5% and the negative predictive value (NPV) was 89.3%. ctHPV DNA was found in plasma before relapse was diagnosed on radiology (median 315 days, mean 280 days) in all patients (n=10) who experienced relapsed after complete clinical response to treatment.
Conclusions
ctHPV DNA in follow-up plasma is a promising prognostic biomarker in patients with locally advanced cervical cancer, useful for analysis of response to therapy and for early detection of relapses. Drs. E. Tham and K. Hellman have equally contributed to the study.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Karolinska Institutet, Magnus Bergvalls Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
648P - Medium to long-term effects of the COVID-19 pandemic on colorectal cancer diagnosis and management in Italy: Preliminary findings from an updated analysis of the real-world multicenter COVID-DELAY study
Presenter: Alessandro Parisi
Session: Poster session 11
649P - The genomic landscape of appendiceal adenocarcinoma (AA) revealed by 855 whole exome sequences (WES)
Presenter: Michael White
Session: Poster session 11
650P - Genomic profiling of small bowel adenocarcinoma: A pooled analysis
Presenter: Thomas Aparicio
Session: Poster session 11
651P - DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: A multicenter propensity score matching study
Presenter: Christophe Borg
Session: Poster session 11
726P - Circulating cell-free DNA-based biomarkers as a new tool for prognosis and surveillance of adrenocortical carcinoma
Presenter: Cristina Ronchi
Session: Poster session 11
727P - Clinical outcome of anlotinib (A) and tislelizumab (T) in metastatic adrenocortical carcinoma(mACC): A one-arm single-center experience
Presenter: HAO LI
Session: Poster session 11
728P - Brain metastases in advanced thyroid carcinoma: Clinical and molecular characteristics and outcomes
Presenter: Thais Megid
Session: Poster session 11
729P - Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs): A survival analysis from a prospective observational study
Presenter: Valentina Andreasi
Session: Poster session 11
730P - The outcome of combine radioligand and CAPTEM therapy in patients with advanced, unresectable, progressive GEP-NET
Presenter: Jaroslaw Cwikla
Session: Poster session 11